Trial Profile
A Study of Brentuximab Vedotin (SGN-35) in CD30-Positive Systemic Mastocytosis With or Without an Associated Hematological Clonal Non-Mast Cell Lineage Disease (AHNMD)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Mast Cell Leukemia; Systemic mastocytosis
- Focus Therapeutic Use
- 16 Feb 2018 Status changed from recruiting to completed.
- 27 Jun 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.
- 27 Jun 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.